BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 28263913)

  • 1. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
    Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
    Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
    Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies.
    Marzban E; Alavizadeh SH; Ghiadi M; Khoshangosht M; Khashayarmanesh Z; Abbasi A; Jaafari MR
    Colloids Surf B Biointerfaces; 2015 Dec; 136():885-91. PubMed ID: 26547316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
    Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
    Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties.
    Huang Z; Szoka FC
    J Am Chem Soc; 2008 Nov; 130(46):15702-12. PubMed ID: 18950160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
    Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
    PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice.
    Alavizadeh SH; Gheybi F; Nikpoor AR; Badiee A; Golmohammadzadeh S; Jaafari MR
    Mol Pharm; 2017 Mar; 14(3):712-721. PubMed ID: 28135098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and cytotoxicity of cisplatin-containing liposomes.
    Carvalho Júnior AD; Vieira FP; Melo VJ; Lopes MT; Silveira JN; Ramaldes GA; Garnier-Suillerot A; Pereira-Maia EC; Oliveira MC
    Braz J Med Biol Res; 2007 Aug; 40(8):1149-57. PubMed ID: 17665053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS.
    Nguyen TT; Ostergaard J; Stürup S; Gammelgaard B
    Int J Pharm; 2013 Jun; 449(1-2):95-102. PubMed ID: 23583709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
    Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
    Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
    J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
    J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
    Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L
    Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models.
    Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR
    Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-octadecylcarbamoylacrylic acid-cisplatin nanocomplexes for the development of novel liposome formulation.
    Song J; Xu T; Zhang Y; Guo H; Ren W; Zhu S; Yang L
    Drug Deliv; 2016 Nov; 23(9):3285-3293. PubMed ID: 27028975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.